Survival Outcomes in ERBB2- Low vs ERBB2- Null Advanced Gastric Cancer - Top-Institutions - MDSpire

Comparative Survival Rates in Advanced Gastric Cancer with Low ERBB2 Expression versus ERBB2 Null Status

  • By

  • Beliz Bahar Karaoğlan

  • Eduardo Terán

  • Pau Mascaró Baselga

  • Adriana Zuchiatti

  • Mirmehdi Mehdiyev

  • Seher Kaya

  • Cevat İlteriş Kıkılı

  • Mahmut Kara

  • Fahriye Tuğba Köş

  • Dılşa Mızrak Kaya

  • Fatih Selçukbiricik

  • Muslih Ürün

  • Pınar Kubilay Tolunay

  • July 21, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Ankara University Faculty of Medicine
    Ankara University Faculty of Medicine

    Ankara, Turkey

    Key Differentiators

    • Oncology

  • #2

    Vall d’Hebron Institute of Oncology
    Vall d’Hebron Institute of Oncology

    Barcelona, Spain

    Key Differentiators

    • Oncology

  • #3

    Koç University Faculty of Medicine
    Koç University Faculty of Medicine

    Istanbul, Turkey

    Key Differentiators

    • Oncology

  • #4

    Van Yüzüncü Yıl University
    Van Yüzüncü Yıl University

    Van, Turkey

    Key Differentiators

    • Oncology

  • #5

    The Cancer Institute Hospital of Japanese Foundation for Cancer Research
    The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Tokyo, Japan

    Key Differentiators

    • Oncology

Original Source(s)

Survival Outcomes in ERBB2- Low vs ERBB2- Null Advanced Gastric Cancer

  • by Beliz Bahar Karaoğlan, Eduardo Terán, Pau Mascaró Baselga, Adriana Zuchiatti, Mirmehdi Mehdiyev, Seher Kaya, Cevat İlteriş Kıkılı, Mahmut Kara, Fahriye Tuğba Köş, Dılşa Mızrak Kaya, Fatih Selçukbiricik, Muslih Ürün, Pınar Kubilay Tolunay

  • July 21, 2026

Related Content

Expression and prognostic significance of INSM1 compared with traditional neuroendocrine markers in mixed urothelial and small-cell carcinoma of the renal pelvis

Inflammatory myofibroblastic tumour: unravelling the interplay of inflammation, kinase signalling, and therapeutic resistance

Hepatic origin of increased serum TFF3 in gastric cancer bearing subjects